{
  "id": 14087237,
  "title": "Big pharmas seal alliances with Chinese groups for $73.6 billion",
  "url": "https://urgent.news/2026/10/12/las-grandes-farmas-sellan-alianzas-con-grupos-chinos-por-73-600",
  "topic": "business",
  "section": "Business",
  "published": "2026-10-12T23:32:16.000Z",
  "source": {
    "name": "Expansion ES",
    "slug": "expansion-es",
    "url": "https://www.expansion.com/empresas/2026/10/13/6accf711468aeb73758b4586.html"
  },
  "original_language": "es",
  "account": "Western pharmaceutical companies are turning to Chinese counterparts for potential blockbuster drugs, driving deals that could exceed $250 billion by 2026. So far this year, major Western pharmaceutical companies have signed agreements with Chinese counterparts worth over $82.4 billion. China is offering Western biopharmaceutical companies hope of finding their next big sellers as their top treatments approach patent expiration. ING estimates that China will account for nearly a third of all new molecules in global pharmaceutical development this year, up from 4% in 2014.",
  "summary": "Western pharmaceutical companies are looking to the Asian giant for their future blockbusters, thereby accelerating deals that could exceed $250 billion in 2026.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}